Use access key #2 to skip to page content.
$0.23 0.00 (0.00%)
8/29/2008 4:00 PM

Cell Therapeutics, Inc. (CTIC)

CAPS Rating:
**

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

CTIC doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

65 Outperforms
14 Underperforms
 

All-Stars

14 Outperforms
7 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on CTIC are also bullish on:

Members bearish on CTIC are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), Micro Cap (4824), Rule Breakers Universe (161), Biotechnology (294)
Suggest a tag

Cell Therapeutics, Inc. At A Glance

Current Price: $0.23
Last Trade Time: 8/29/2008 4:00 PM
Open: $0.00
Previous Close: $0.23
Daily Range: $0.23 - $0.25
52-Week Range: $2.31 - $40.00
Volume: 458,458
Market Cap: $38.93M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CTIC VS S&P 500 (SPY)

CTIC 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for CTIC

More Headlines...

Top Bull Pitch

Recs

1

Cell Therapeutics, Inc. (CTIC)

Avatar leonard228 (49.21) Submitted: 3/19/07 9:15 AM

A few very good possibilitys in the pipeline but management seems to be "managing" very well at this juncture. "High risk" but if any of the additional phase III trials pan out, FDA approval will soon follow. Recent new partners will help.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 13 :   1 2 3 Next »

Recs

0

 (CTIC)

Avatar mp21 (31.45) Submitted: 11/20/07 3:47 PM : Outperform Start Price: $2.55 CTIC Score: -77.05

unloved stock for now. cancer treatment. long-term pharma play. good pipeline. historical stock price performance looks bad, but there is a huge upside when new drugs hit the market. analysts say 'Buy'.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CTIC)

Avatar gavinsblog (< 20) Submitted: 7/09/07 1:40 PM : Outperform Start Price: $4.17 CTIC Score: -75.48

Cancer spec

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CTIC)

Avatar certitguy (< 20) Submitted: 6/21/07 6:15 PM : Outperform Start Price: $2.98 CTIC Score: -74.11

I think the way the FDA is shooting down these new drug discoveries it's a good chance a lot of these pharma companies will either go under or struggle. The FDA is corrupt just like our government, whoever has the most money gets what they need. I own shares and I'm just going to ride the ups and downs until something significant happens.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CTIC)

Avatar asemritc (97.75) Submitted: 6/13/07 11:16 AM : Underperform Start Price: $3.43 CTIC Score: 75.65

Too much uncertainty

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CTIC)

Avatar kanstockman (< 20) Submitted: 6/11/07 2:45 PM : Underperform Start Price: $3.52 CTIC Score: 75.21

2008 a drug in Phase III stage II should be on the market with a half a billion in sales by the 2nd Q. Right now the stock is being dragged down by the sector componants.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 13 :   1 2 3 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRodmanRen 52.05 01/08/07 Outperform NS $6.96-96.68%-11.91%-84.77

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners